{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:40:26Z","timestamp":1787841626979,"version":"build-2784847793"},"reference-count":29,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006775","name":"GE Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006775","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032121","name":"Lundbeck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032121","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014593","name":"Neurocrine Biosciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018044","name":"Verily Life Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018044","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018556","name":"Voyager Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018556","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019889","name":"Weston Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019889","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Annals of Neurology"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      Dopaminergic imaging is a key biomarker for both the investigation of the biology of Parkinson's disease and related synucleinopathies and the evaluation of potential therapies in clinical trials. This work presents a harmonized approach for quantifying dopaminergic molecular imaging tracers, such as [\n                      <jats:sup>123<\/jats:sup>\n                      I]ioflupane (dopamine transporter scan [DaTscan]) single photon emission computed tomography (SPECT) and [\n                      <jats:sup>18<\/jats:sup>\n                      F]AV133 positron emission tomography (PET), which assess dopaminergic neuronal loss. The proposed method aims to standardize regional outcome measures using a unified scale called Centamines.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The Centamines framework comprises 3 analysis levels. Level 1 defines the Centamine scale based on healthy subject data from [\n                      <jats:sup>123<\/jats:sup>\n                      I]ioflupane SPECT (n\u2009=\u2009224). Level 2 uses head\u2010to\u2010head data between Tracer X and [\n                      <jats:sup>123<\/jats:sup>\n                      I]ioflupane SPECT to map Tracer X onto the Centamine scale. Level 3 maps additional tracers using prior mappings. A level 2 analysis was performed using [\n                      <jats:sup>123<\/jats:sup>\n                      I]ioflupane SPECT and [\n                      <jats:sup>18<\/jats:sup>\n                      F]AV133 PET data (n\u2009=\u200968) to convert [\n                      <jats:sup>18<\/jats:sup>\n                      F]AV133 PET into Centamines.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Level 1 successfully established the Centamine scale using healthy [\n                      <jats:sup>123<\/jats:sup>\n                      I]ioflupane SPECT scans. Level 2 revealed moderate\u2010strong linear correlations (\n                      <jats:italic>R<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090.51\u20130.83) between [\n                      <jats:sup>123<\/jats:sup>\n                      I]ioflupane SPECT and [\n                      <jats:sup>18<\/jats:sup>\n                      F]AV133 PET across 5 brain regions. Mapped Centamine values showed minimal differences between tracers, ranging from 1.5% (post\u2010commissural putamen) to 3% (caudate).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation<\/jats:title>\n                    <jats:p>The Centamine scale holds promise for the harmonized quantification of dopaminergic neuronal imaging markers. The Centamine strategy would enable and accelerate clinical trials in Parkinson's disease using dopaminergic imaging outcomes. ANN NEUROL 2026;99:949\u2013963<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ana.78116","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T11:04:31Z","timestamp":1768907071000},"page":"949-963","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Toward Harmonizing Quantification of Dopamine Neuron Imaging Biomarkers in Parkinson's Disease: The Centamine Scale"],"prefix":"10.1002","volume":"99","author":[{"given":"Zhen","family":"Fan","sequence":"first","affiliation":[{"name":"Xing Imaging\u2010A Mitro Company  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Searle","sequence":"additional","affiliation":[{"name":"Xing Imaging\u2010A Mitro Company  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Rizzo","sequence":"additional","affiliation":[{"name":"Xing Imaging\u2010A Mitro Company  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Albani","sequence":"additional","affiliation":[{"name":"Xing Imaging\u2010A Mitro Company  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4333-1178","authenticated-orcid":false,"given":"Patrick","family":"Cella","sequence":"additional","affiliation":[{"name":"GE HealthCare  Arlington Heights Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Comley","sequence":"additional","affiliation":[{"name":"AbbVie  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Klein","sequence":"additional","affiliation":[{"name":"F. Hoffmann\u2010La Roche  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Passamonti","sequence":"additional","affiliation":[{"name":"Lantheus Medical Imaging  Billerica Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Salinas","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9743-6171","authenticated-orcid":false,"given":"Adam J.","family":"Schwarz","sequence":"additional","affiliation":[{"name":"GE HealthCare  Arlington Heights Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Iaccarino","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Tamagnan","sequence":"additional","affiliation":[{"name":"Xing Imaging\u2010A Mitro Company  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Eberling","sequence":"additional","affiliation":[{"name":"The Michael J. Fox Foundation Research Resources  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Marek","sequence":"additional","affiliation":[{"name":"Institute for Neurodegenerative Disorders  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Seibyl","sequence":"additional","affiliation":[{"name":"Institute for Neurodegenerative Disorders  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1181-5769","authenticated-orcid":false,"given":"Roger N.","family":"Gunn","sequence":"additional","affiliation":[{"name":"Xing Imaging\u2010A Mitro Company  London UK"},{"name":"Department of Brain Sciences, Faculty of Medicine Imperial College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The Parkinson's Progression Markers Initiative","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00109-6"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00405-2"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00404-0"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.62.2.133"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-009-1267-x"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(200005)15:3<503::AID-MDS1013>3.0.CO;2-V"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51122"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-006-0322-9"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.111.101626"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04587-y"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.189019"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207748"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.109.070094"},{"key":"e_1_2_9_15_1","unstructured":"FanZ SearleG WhittingtonA et al.Increasing the power of [18F]AV133 PET to measure longitudinal changes in Parkinson's Disease: Identification of optimal reference and target regions. AD\/PD\u2122 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders Gothenburg Sweden 2023."},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2014.07.003"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14336"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/00019442-200201000-00005"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13908"},{"key":"e_1_2_9_21_1","doi-asserted-by":"crossref","unstructured":"TannerC MarekK.Parkinson's Progression Markers Initiative Online Study (PPMI Online) v1 2024.","DOI":"10.17504\/protocols.io.q26g718y9gwz\/v1"},{"key":"e_1_2_9_22_1","doi-asserted-by":"crossref","unstructured":"MarekK.Early Longitudinal Imaging in the Parkinson's Progression Markers Initiative Using [ 18F] AV\u2010133 (PPMI AV\u2010133 Prodromal Imaging) v1 2024.","DOI":"10.17504\/protocols.io.bp2l62nqkgqe\/v1"},{"key":"e_1_2_9_23_1","first-page":"1928","article-title":"Molecular imaging and kinetic analysis toolbox (MIAKAT) \u2010 a quantitative software package for the analysis of PET neuroimaging data","volume":"57","author":"Gunn R","year":"2016","journal-title":"J Nucl Med"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2010.06.044"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2007.07.007"},{"key":"e_1_2_9_26_1","first-page":"1175","article-title":"Age\u2010related decline in striatal dopamine transporter binding with Iodine\u2010123\u2010\u03b2\u2010CITSPECT","volume":"36","author":"Van Dyck CH","year":"1995","journal-title":"J Nucl Med"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002590000279"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/tomography7040081"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/tomography10100119"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.194720"}],"container-title":["Annals of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ana.78116","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ana.78116","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ana.78116","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:15:42Z","timestamp":1787840142000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ana.78116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/ana.78116"],"URL":"https:\/\/doi.org\/10.1002\/ana.78116","archive":["Portico"],"relation":{},"ISSN":["0364-5134","1531-8249"],"issn-type":[{"value":"0364-5134","type":"print"},{"value":"1531-8249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"2025-07-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}